Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism
- PMID: 10702395
- PMCID: PMC1876838
- DOI: 10.1016/s0002-9440(10)64947-4
Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism
Abstract
The levels of amyloid-beta40 (Abeta40) and Abeta42 peptides were quantified in temporalis muscles and brain of neuropathologically diagnosed Alzheimer disease (AD) and of nondemented individuals. This was achieved by using a novel analytical approach consisting of a combination of fast-performance liquid chromatographic (FPLC) size exclusion chromatography developed under denaturing conditions and europium immunoassay on the 4.0- to 4.5-kd fractions. In the temporalis muscles of the AD and nondemented control groups, the average values for Abeta42 were 15.7 ng/g and 10.2 ng/g (P = 0.010), and for Abeta40 they were 37.8 ng/g and 29.8 ng/g (P = 0.067), respectively. Multiple regression analyses of the AD and control combined populations indicated that 1) muscle Abeta40 and muscle Abeta42 levels were correlated with each other (P < 0.001), 2) muscle Abeta40 levels were positively correlated with age (P = 0. 036), and 3) muscle Abeta42 levels were positively correlated with Braak stage (P = 0.042). Other forms of the Abeta peptide were discovered by mass spectrometry, revealing the presence of Abeta starting at residues 1, 6, 7, 9, 10, and 11 and ending at residues 40, 42, 44, 45, and 46. It is possible that in AD the skeletal muscle may contribute to the elevated plasma pool of Abeta and thus indirectly to the amyloid deposits of the brain parenchyma and cerebral blood vessels. The increased levels of Abeta in the temporalis muscles of AD patients suggest that alterations in AbetaPP and Abeta metabolism may be manifested in peripheral tissues.
Figures
References
-
- Selkoe DJ: Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci 1994, 17:489-517 - PubMed
-
- Joachim CL, Mori H, Selkoe DJ: Amyloid β-protein deposition in tissues other than brain in Alzheimer’s disease. Nature 1989, 341:226-230 - PubMed
-
- Golde TE, Estus S, Usiak M, Younkin LH, Younkin SG: Expression of β amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer’s disease using PCR. Neuron 1990, 4:253-267 - PubMed
-
- Li QX, Whyte S, Tanner JE, Evin G, Beyreuther K, Masters CL: Secretion of Alzheimer’s disease Aβ amyloid peptide by activated human platelets. Lab Invest 1998, 78:461-469 - PubMed
-
- Nordstedt C, Naslund J, Thyberg J, Messamore E, Gandy SE, Terenius L: Human neutrophil phagocytic granules contain a truncated soluble form of the Alzheimer β/A4 amyloid precursor protein (APP). J Biol Chem 1994, 269:9805-9810 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
